DNAJC5 and malaria: Vaccine clinical trials for P. falciparum have moved decisively forward, and leading pre-erythrocytic P. falciparum candidates (R21, RTS, S, and Ad-M ME.TRAP) based on CSP and TRAP proteins alone or in combination have been tested in a control human malaria infection with encouraging results showing that such vaccines offer partial protection against malaria sporozoite challenge on their own [24].